Pediatric Growth Hormone Deficiency Global Market Report 2025

The pediatric growth hormone deficiency market size has grown strongly in recent years. It will grow from $3.8 billion in 2024 to $4.16 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be credited to greater awareness of pediatric growth disorder treatments, enhanced diagnostic capabilities, increased investments in research and development of next-generation products, and the expansion of public insurance schemes.

The pediatric growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth during the forecast period can be attributed to the expansion of healthcare infrastructure and access to care, advancements in growth hormone therapies, increased awareness and patient advocacy, supportive government policies and healthcare initiatives, and the rising prevalence of PGHD. Key trends in the forecast period include the development of novel therapies, personalized treatment approaches, product innovation, telemedicine and remote monitoring, as well as advancements in personalized medicine and genetic testing.

The rising prevalence of pediatric diseases is anticipated to drive the growth of the pediatric growth hormone deficiency market. Pediatric diseases encompass medical conditions or illnesses that primarily affect children from infancy to adolescence. The increasing occurrence of these diseases can be attributed to environmental factors, advancements in detection methods, lifestyle changes, genetic predispositions, and a growing incidence of chronic conditions and allergies among children. Such diseases can contribute to pediatric growth hormone deficiency (GHD) by impacting the hypothalamus or pituitary gland, which are responsible for growth hormone production. For example, according to the United Nations Children's Fund (UNICEF), a US-based government organization, approximately 4.9 million children under the age of five lost their lives in 2022, averaging 13,400 deaths per day. Leading global causes of under-five mortality included infectious diseases such as pneumonia, diarrhea, and malaria, along with complications from preterm birth and intrapartum-related issues. As a result, the increasing prevalence of pediatric diseases is fueling the expansion of the pediatric growth hormone deficiency market.

Companies operating in this market are prioritizing the development of innovative treatments, including long-acting, once-weekly human growth hormone analogs, to enhance patient compliance and convenience. A long-acting, once-weekly human growth hormone (HGH) analog is a modified version of natural human growth hormone, designed to have a prolonged duration of action in the body. For instance, in June 2023, Pfizer Inc., a US-based pharmaceutical company, and OPKO Health Inc., a US-based medication company, jointly announced the approval of NGENLA (somatrogon-ghla) by the Food and Drug Administration (FDA), a US-based government agency. This once-weekly human growth hormone analog is intended for pediatric patients aged three years and older who experience growth failure due to inadequate secretion of endogenous growth hormone. The treatment aims to improve patient adherence by reducing the frequency of injections, as traditional therapies typically require daily dosing. Clinical trials have demonstrated that NGENLA provides efficacy comparable to daily growth hormone treatments, offering a more convenient and manageable solution for children and their families.

In December 2024, Double Point Ventures, a US-based venture capital fund, acquired Lumos Pharma for $38 million. This acquisition is intended to accelerate the development of Lumos' lead therapeutic candidate, LUM-201, while expanding its portfolio of treatments for rare diseases. Lumos Pharma, a US-based biopharmaceutical company, specializes in developing therapies for rare diseases, particularly those associated with growth hormone deficiencies.

Major players in the pediatric growth hormone deficiency market are Pfizer Inc., Eli Lilly and Company, Novo Nordisk A/S, Genentech Inc., Merck KGaA Darmstadt Germany, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., I-Mab Biopharma Co. Ltd., Ipsen Pharma, Gedeon Richter Plc, Ferring Pharmaceuticals, Celltrion Healthcare Co. Ltd., OPKO Health Inc., Zhejiang Hisun Pharmaceutical Co., Ltd., Dong-A ST Co. Ltd., Ascendis Pharma A/S, AnkeBio, Versartis Inc., Changchun Changsheng Life Sciences Ltd.

North America was the largest region in the pediatric growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pediatric growth hormone deficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pediatric growth hormone deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pediatric growth hormone deficiency (PGHD) is a condition where the pituitary gland fails to produce adequate growth hormone, resulting in slow growth, short stature, and delayed puberty. This condition can be either congenital or acquired, with treatment usually involving recombinant human growth hormone (rhGH) therapy to help ensure normal growth and development.

The primary types of pediatric growth hormone deficiency are congenital GH deficiency, acquired GH deficiency, and idiopathic GH deficiency. Congenital growth hormone deficiency (GHD) is a rare condition present from birth, where the body cannot produce enough growth hormone. Various treatments are available, including recombinant human growth hormone (rhGH), human growth hormone (hGH) analogs, and long-acting growth hormones, which can be administered via subcutaneous, intramuscular, or oral routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used to address conditions such as growth hormone deficiency, idiopathic short stature, Turner syndrome, small for gestational age, Prader-Willi syndrome, and more.

The pediatric growth hormone deficiency market research report is one of a series of new reports that provides pediatric growth hormone deficiency market statistics, including pediatric growth hormone deficiency industry global market size, regional shares, competitors with a pediatric growth hormone deficiency market share, detailed pediatric growth hormone deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric growth hormone deficiency industry. This pediatric growth hormone deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pediatric growth hormone deficiency market consists of sales of synthetic growth hormone, growth hormone releasing hormone, and long-acting growth hormone therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.